RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Patient-directed oncology
therapies across immune and
cancer cell pathways

Rapidly developing new
cancer treatments for
people of all ages

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Applying new insights in
hepcidin biology to
treat hematologic diseases

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

New class of
regulated cell and
gene therapies

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Novel therapeutics
targeting
diseases of aging

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Bispecific antibodies
to improve the treatment
of serious diseases

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Creating breakthrough
therapies for neurological
and psychiatric conditions

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Next generation ocular gene
therapies for vision restoration
and vision preservation

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Harnessing the immune system
to defeat cancer with
tumor-selective immunotherapies

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Developing medicines
that target inflammation
at its core

Discovering new medicines
for severe
neurodegenerative diseases

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Breakthrough computer-aided
drug design
for transformative medicines

Disease modifying therapies
for patients with rare
cardiopulmonary disease

Translating natural
RNA editing into new
possibilities for patients

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Preventing axonal degeneration
in patients with
neurological diseases

Building
the future of
gene therapy

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)